Table 2B
Open in new tab

Association between ApoA1 levels and adverse outcomes. Male only cohort.

OutcomeModel0.42–1.17 g/L (95% CI)1.18–1.24 g/L (95% CI)1.25–1.30 g/L (95% CI)1.31–1.36 g/L (95% CI)1.37–1.41 g/L (95% CI)1.42–1.47 g/L (95% CI)1.48–1.53 g/L (reference)1.54–1.61 g/L (95% CI)1.62–1.73 g/L (95% CI)1.74–2.50 g/L (95% CI)
All-cause mortalityUnadjusted1.68 (1.56–1.80); P < 0.00011.36 (1.26–1.47); P < 0.00011.18 (1.09–1.27); P < 0.00011.10 (1.02–1.19); P = 0.01351.07 (0.99–1.15); P = 0.10041.02 (0.94–1.10); P = 0.67971.000.99 (0.92–1.07); P = 0.8151.01 (0.94–1.10); P = 0.74061.23 (1.14–1.32); P < 0.0001
Adjusteda1.40 (1.30–1.52); P < 0.00011.22 (1.13–1.32); P < 0.00011.09 (1.01–1.18); P = 0.03571.04 (0.96–1.13); P = 0.29161.03 (0.95–1.12); P = 0.342040.99 (0.92–1.08); P = 0.89081.001.01 (0.93–1.09); P = 0.90581.04 (0.96–1.12); P = 0.3551.27 (1.18–1.37); P < 0.0001
PGS Adjustedb1.38 (1.28–1.49); P < 0.00011.21 (1.12–1.30); P < 0.00011.08 (1.00–1.17); P = 0.06231.03 (0.95–1.12); P = 0.43311.03 (0.95–1.11); P = 0.51841.00 (0.92–1.08); P = 0.89441.001.01 (0.93–1.09); P = 0.80681.04 (0.96–1.13); P = 0.29771.29 (1.19–1.39); P < 0.0001
CV mortalityUnadjusted2.04 (1.80–2.31); P < 0.00011.59 (1.39–1.81); P < 0.00011.34 (1.17–1.53); P < 0.00011.16 (1.01–1.33) P = 0.0371.24 (1.08–1.42) P = 0.00231.16 (1.01–1.33); P = 0.03631.001.09 (0.95–1.25); P = 0.23430.97 (0.84–1.12); P = 0.70251.28 (1.12–1.46) P = 0.0002
Adjusteda1.52 (1.33–1.74); P < 0.00011.29 (1.12–1.48); P < 0.00011.17 (1.02–1.35); P = 0.02791.05 (0.91–1.21); P = 0.53691.15 (1.00–1.33); P = 0.0481.11 (0.96–1.28); P = 0.15041.001.13 (0.98–1.31); P = 0.08311.05 (0.90–1.21); P = 0.55591.44 (1.26–1.65); P < 0.0001
PGS Adjustedb1.50 (1.30–1.72); P < 0.00011.27 (1.11–1.46); P = 0.00071.16 (1.01–1.34); P = 0.04211.04 (0.90–1.20) P = 0.62981.15 (1.00–1.33) P = 0.05011.12 (0.97–1.29); P = 0.12831.001.15 (1.00–1.33); P = 0.0591.07 (0.92–1.24); P = 0.38951.48 (1.29–1.70) P < 0.0001
OutcomeModel0.42–1.17 g/L (95% CI)1.18–1.24 g/L (95% CI)1.25–1.30 g/L (95% CI)1.31–1.36 g/L (95% CI)1.37–1.41 g/L (95% CI)1.42–1.47 g/L (95% CI)1.48–1.53 g/L (reference)1.54–1.61 g/L (95% CI)1.62–1.73 g/L (95% CI)1.74–2.50 g/L (95% CI)
All-cause mortalityUnadjusted1.68 (1.56–1.80); P < 0.00011.36 (1.26–1.47); P < 0.00011.18 (1.09–1.27); P < 0.00011.10 (1.02–1.19); P = 0.01351.07 (0.99–1.15); P = 0.10041.02 (0.94–1.10); P = 0.67971.000.99 (0.92–1.07); P = 0.8151.01 (0.94–1.10); P = 0.74061.23 (1.14–1.32); P < 0.0001
Adjusteda1.40 (1.30–1.52); P < 0.00011.22 (1.13–1.32); P < 0.00011.09 (1.01–1.18); P = 0.03571.04 (0.96–1.13); P = 0.29161.03 (0.95–1.12); P = 0.342040.99 (0.92–1.08); P = 0.89081.001.01 (0.93–1.09); P = 0.90581.04 (0.96–1.12); P = 0.3551.27 (1.18–1.37); P < 0.0001
PGS Adjustedb1.38 (1.28–1.49); P < 0.00011.21 (1.12–1.30); P < 0.00011.08 (1.00–1.17); P = 0.06231.03 (0.95–1.12); P = 0.43311.03 (0.95–1.11); P = 0.51841.00 (0.92–1.08); P = 0.89441.001.01 (0.93–1.09); P = 0.80681.04 (0.96–1.13); P = 0.29771.29 (1.19–1.39); P < 0.0001
CV mortalityUnadjusted2.04 (1.80–2.31); P < 0.00011.59 (1.39–1.81); P < 0.00011.34 (1.17–1.53); P < 0.00011.16 (1.01–1.33) P = 0.0371.24 (1.08–1.42) P = 0.00231.16 (1.01–1.33); P = 0.03631.001.09 (0.95–1.25); P = 0.23430.97 (0.84–1.12); P = 0.70251.28 (1.12–1.46) P = 0.0002
Adjusteda1.52 (1.33–1.74); P < 0.00011.29 (1.12–1.48); P < 0.00011.17 (1.02–1.35); P = 0.02791.05 (0.91–1.21); P = 0.53691.15 (1.00–1.33); P = 0.0481.11 (0.96–1.28); P = 0.15041.001.13 (0.98–1.31); P = 0.08311.05 (0.90–1.21); P = 0.55591.44 (1.26–1.65); P < 0.0001
PGS Adjustedb1.50 (1.30–1.72); P < 0.00011.27 (1.11–1.46); P = 0.00071.16 (1.01–1.34); P = 0.04211.04 (0.90–1.20) P = 0.62981.15 (1.00–1.33) P = 0.05011.12 (0.97–1.29); P = 0.12831.001.15 (1.00–1.33); P = 0.0591.07 (0.92–1.24); P = 0.38951.48 (1.29–1.70) P < 0.0001

Cox proportional hazards models were used for all-cause death; Fine and Gray’s sub-distribution hazard models were used for cardiovascular death, treating the non-cardiovascular deaths as competing risks.

Adjusted for age, race, body mass index, hypertension, diabetes, current/former smoking, frequency of alcohol use (defined as graded variable on scale of 0–5), triglycerides, LDL-C, eGFR.

Adjusted for age, race, body mass index, hypertension, diabetes, current/former smoking, frequency of alcohol use (defined as graded variable on scale of 0–5), triglycerides, LDL-C, eGFR, PGS and top 10 principal components.

Statistical significance defined at P < 0.05 (bold font).

Table 2B
Open in new tab

Association between ApoA1 levels and adverse outcomes. Male only cohort.

OutcomeModel0.42–1.17 g/L (95% CI)1.18–1.24 g/L (95% CI)1.25–1.30 g/L (95% CI)1.31–1.36 g/L (95% CI)1.37–1.41 g/L (95% CI)1.42–1.47 g/L (95% CI)1.48–1.53 g/L (reference)1.54–1.61 g/L (95% CI)1.62–1.73 g/L (95% CI)1.74–2.50 g/L (95% CI)
All-cause mortalityUnadjusted1.68 (1.56–1.80); P < 0.00011.36 (1.26–1.47); P < 0.00011.18 (1.09–1.27); P < 0.00011.10 (1.02–1.19); P = 0.01351.07 (0.99–1.15); P = 0.10041.02 (0.94–1.10); P = 0.67971.000.99 (0.92–1.07); P = 0.8151.01 (0.94–1.10); P = 0.74061.23 (1.14–1.32); P < 0.0001
Adjusteda1.40 (1.30–1.52); P < 0.00011.22 (1.13–1.32); P < 0.00011.09 (1.01–1.18); P = 0.03571.04 (0.96–1.13); P = 0.29161.03 (0.95–1.12); P = 0.342040.99 (0.92–1.08); P = 0.89081.001.01 (0.93–1.09); P = 0.90581.04 (0.96–1.12); P = 0.3551.27 (1.18–1.37); P < 0.0001
PGS Adjustedb1.38 (1.28–1.49); P < 0.00011.21 (1.12–1.30); P < 0.00011.08 (1.00–1.17); P = 0.06231.03 (0.95–1.12); P = 0.43311.03 (0.95–1.11); P = 0.51841.00 (0.92–1.08); P = 0.89441.001.01 (0.93–1.09); P = 0.80681.04 (0.96–1.13); P = 0.29771.29 (1.19–1.39); P < 0.0001
CV mortalityUnadjusted2.04 (1.80–2.31); P < 0.00011.59 (1.39–1.81); P < 0.00011.34 (1.17–1.53); P < 0.00011.16 (1.01–1.33) P = 0.0371.24 (1.08–1.42) P = 0.00231.16 (1.01–1.33); P = 0.03631.001.09 (0.95–1.25); P = 0.23430.97 (0.84–1.12); P = 0.70251.28 (1.12–1.46) P = 0.0002
Adjusteda1.52 (1.33–1.74); P < 0.00011.29 (1.12–1.48); P < 0.00011.17 (1.02–1.35); P = 0.02791.05 (0.91–1.21); P = 0.53691.15 (1.00–1.33); P = 0.0481.11 (0.96–1.28); P = 0.15041.001.13 (0.98–1.31); P = 0.08311.05 (0.90–1.21); P = 0.55591.44 (1.26–1.65); P < 0.0001
PGS Adjustedb1.50 (1.30–1.72); P < 0.00011.27 (1.11–1.46); P = 0.00071.16 (1.01–1.34); P = 0.04211.04 (0.90–1.20) P = 0.62981.15 (1.00–1.33) P = 0.05011.12 (0.97–1.29); P = 0.12831.001.15 (1.00–1.33); P = 0.0591.07 (0.92–1.24); P = 0.38951.48 (1.29–1.70) P < 0.0001
OutcomeModel0.42–1.17 g/L (95% CI)1.18–1.24 g/L (95% CI)1.25–1.30 g/L (95% CI)1.31–1.36 g/L (95% CI)1.37–1.41 g/L (95% CI)1.42–1.47 g/L (95% CI)1.48–1.53 g/L (reference)1.54–1.61 g/L (95% CI)1.62–1.73 g/L (95% CI)1.74–2.50 g/L (95% CI)
All-cause mortalityUnadjusted1.68 (1.56–1.80); P < 0.00011.36 (1.26–1.47); P < 0.00011.18 (1.09–1.27); P < 0.00011.10 (1.02–1.19); P = 0.01351.07 (0.99–1.15); P = 0.10041.02 (0.94–1.10); P = 0.67971.000.99 (0.92–1.07); P = 0.8151.01 (0.94–1.10); P = 0.74061.23 (1.14–1.32); P < 0.0001
Adjusteda1.40 (1.30–1.52); P < 0.00011.22 (1.13–1.32); P < 0.00011.09 (1.01–1.18); P = 0.03571.04 (0.96–1.13); P = 0.29161.03 (0.95–1.12); P = 0.342040.99 (0.92–1.08); P = 0.89081.001.01 (0.93–1.09); P = 0.90581.04 (0.96–1.12); P = 0.3551.27 (1.18–1.37); P < 0.0001
PGS Adjustedb1.38 (1.28–1.49); P < 0.00011.21 (1.12–1.30); P < 0.00011.08 (1.00–1.17); P = 0.06231.03 (0.95–1.12); P = 0.43311.03 (0.95–1.11); P = 0.51841.00 (0.92–1.08); P = 0.89441.001.01 (0.93–1.09); P = 0.80681.04 (0.96–1.13); P = 0.29771.29 (1.19–1.39); P < 0.0001
CV mortalityUnadjusted2.04 (1.80–2.31); P < 0.00011.59 (1.39–1.81); P < 0.00011.34 (1.17–1.53); P < 0.00011.16 (1.01–1.33) P = 0.0371.24 (1.08–1.42) P = 0.00231.16 (1.01–1.33); P = 0.03631.001.09 (0.95–1.25); P = 0.23430.97 (0.84–1.12); P = 0.70251.28 (1.12–1.46) P = 0.0002
Adjusteda1.52 (1.33–1.74); P < 0.00011.29 (1.12–1.48); P < 0.00011.17 (1.02–1.35); P = 0.02791.05 (0.91–1.21); P = 0.53691.15 (1.00–1.33); P = 0.0481.11 (0.96–1.28); P = 0.15041.001.13 (0.98–1.31); P = 0.08311.05 (0.90–1.21); P = 0.55591.44 (1.26–1.65); P < 0.0001
PGS Adjustedb1.50 (1.30–1.72); P < 0.00011.27 (1.11–1.46); P = 0.00071.16 (1.01–1.34); P = 0.04211.04 (0.90–1.20) P = 0.62981.15 (1.00–1.33) P = 0.05011.12 (0.97–1.29); P = 0.12831.001.15 (1.00–1.33); P = 0.0591.07 (0.92–1.24); P = 0.38951.48 (1.29–1.70) P < 0.0001

Cox proportional hazards models were used for all-cause death; Fine and Gray’s sub-distribution hazard models were used for cardiovascular death, treating the non-cardiovascular deaths as competing risks.

Adjusted for age, race, body mass index, hypertension, diabetes, current/former smoking, frequency of alcohol use (defined as graded variable on scale of 0–5), triglycerides, LDL-C, eGFR.

Adjusted for age, race, body mass index, hypertension, diabetes, current/former smoking, frequency of alcohol use (defined as graded variable on scale of 0–5), triglycerides, LDL-C, eGFR, PGS and top 10 principal components.

Statistical significance defined at P < 0.05 (bold font).

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close